Latest Seek News

Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.

Singular Health has signed a non-binding MOU to build and operate a medical imaging repository for Florida Medicaid, with approximately A$3.5 million of potential revenue subject to definitive agreements and delivery. The project could give its 3DICOM platform a state-funded infrastructure reference site, but recurring funding remains unassured.

Heartland Group Holdings (NZX: HGH, ASX: HGH) more than doubled FY2026 net profit as margins widened, asset quality improved and its proposed TSB merger moved towards a shareholder vote. The bank also reported a 16% fall in restated emissions, though much of its climate-risk work remains incomplete or estimate-driven.

Global X Nasdaq 100 Covered Call Complex ETF reported a sharp improvement in annual profit, helped by a swing to fair-value gains and continued investor applications. The ASX-listed feeder fund paid or accrued $2.731 million in distributions, but the result does not show whether investors achieved a positive total return after unit-price movements.

Alice Queen has outlined a potentially lucrative Horn Island development case, but the numbers remain preliminary and depend on further drilling, approvals and funding. The gold explorer ended FY2026 with a A$3.55 million loss and A$3.6 million in cash.

NGX Limited (ASX:NGX) has warned of a material uncertainty over its ability to continue as a going concern after cash reserves fell to A$1.65 million. The minerals explorer says it will need additional working capital through September 2027, despite advancing graphite, rutile and uranium projects.

Brazilian Critical Minerals has reported striking economics for its Ema rare earths project, including a US$1.47 billion post-tax NPV, 105% IRR and six-month payback. The company’s A$7.87 million FY2026 loss, December debt maturity, permitting requirements and unresolved Drake dispute leave the development case dependent on execution and further funding.

Otto Energy plans to return approximately A$20 million to shareholders after consolidating its shares 100:1, with the proposed payment set at A$0.417 per post-consolidation share. The proposals require approval at the company’s 13 November 2026 AGM and remain subject to an outstanding ATO tax ruling.

Paradigm Biopharmaceuticals will keep its ASX securities suspended until at least 30 September while it reviews interim Phase 3 data and assesses the operational and financial consequences. The company also remains in discussions with Obsidian Global GP, LLC, but has not disclosed the trial results or their direction.

BSA Limited (ASX:BSA) has entered an immediate voluntary suspension while it prepares to disclose a material acquisition. The company expects to make the announcement by market open on 30 September, but has provided no details on the target, value or funding.

Felix Group Holdings has secured A$5.54 million in institutional funding and launched a further A$1 million shareholder purchase plan as it pivots towards an open procurement platform. The ASX-listed software company is also guiding to at least 15% revenue growth in FY27.

Dateline Resources has gained a powerful ally in its bid to restart the Colosseum project, with the US Government asking a federal court to suspend the injunction blocking operations. A Department of War declaration argues the California rare earth project serves US economic and national security interests, but the stay remains undecided.